3 Integrated Steel and Power Company, Oil and Gas Explorer and Specialty Pharmaceutical Company Stocks With a Strong Future Roadmap: Sarda Energy, Oil India and Sun Pharma
- November 11, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Sarda Energy, Oil India and Sun Pharma: ROE of 11.4% to 15.0% and FY22 to FY26 revenue CAGR of 7.3% to 11.6%. Prices as of 10 Nov 2026.
Quick Answer
The three steel and power, oil explorer and pharma stocks to watch are Sarda Energy, Oil India and Sun Pharma. Their return on equity ranges from 11.4% to 15.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.3% to 11.6%. Sarda Energy has the highest return on equity at 15.0%, while Sun Pharma has the fastest revenue growth at 11.6% a year. Prices are based on the 10 November 2026 close, and this article is educational, not investment advice.
Steel and power, oil explorer and pharma stocks let investors follow companies that serve a growing part of the Indian economy. Sarda Energy, Oil India and Sun Pharma cover an integrated steel and power company, an oil and gas explorer and a specialty pharmaceutical company.
This list covers three steel and power, oil explorer and pharma stocks with complete current figures: Sarda Energy, Oil India and Sun Pharma. Every figure comes from the latest reported financials and the 10 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Steel and Power, Oil Explorer and Pharma Stocks?
Steel and power, oil explorer and pharma stocks are listed companies that make steel, ferro alloys and power, explore for and produce crude oil and natural gas, and develop and sell generic and specialty medicines in India and abroad. Their earnings depend on steel and alloy demand, oil and gas output and prescription demand.
Steel and Power, Oil Explorer and Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Sarda Energy | 439.95 | 16,079 | 14.0 | 22.4 | 15.0 | 0.36 |
| Oil India | 439 | 72,563 | 7.6 | 7.2 | 11.4 | 0.65 |
| Sun Pharma | 1,904.5 | 422,283 | 34.9 | 36.2 | 13.7 | 0.06 |
On valuation, Sarda Energy and Sun Pharma trade at a P/E below the industry P/E, while Oil India trades above it, which reflects the growth the market already expects. Readers comparing steel and power, oil explorer and pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in steel and power, oil explorer and pharma stocks can use the coming numbers to test whether growth is holding.
Why Do Steel and Power, Oil Explorer and Pharma Stocks Have a Strong Roadmap in India?
Steel and power, oil explorer and pharma stocks have a strong roadmap in India because rising infrastructure spending, steady energy needs and growing global demand for medicines keep widening the market for these companies.
- Steel and power. Construction and industry need steady steel.
- Oil and gas. Homes and factories need reliable fuel.
- Pharma. Specialty medicines find wider markets.
Why Sarda Energy Features Among These Steel and Power, Oil Explorer and Pharma Stocks
Among the steel and power, oil explorer and pharma stocks on this list, Sarda Energy and Minerals is a Raipur-based integrated company producing ferro alloys, sponge iron, steel billets and power, supported by its own mines.
Revenue rose from Rs 3,964 crore in FY22 to Rs 5,928 crore in FY26, a compound annual growth rate of 10.6%. Net profit grew from Rs 808 crore in FY22 to Rs 1,063 crore in FY26, which works out to a compound annual growth rate of 7.1%.
In the June 2026 quarter, revenue grew 0.2% year on year to Rs 1,717 crore, while net profit rose 9.4% to Rs 463 crore. The company has a return on equity of 15.0%, a debt to equity ratio of 0.36 and a market capitalisation of Rs 16,079 crore. The stock trades at a P/E of 14.0, below the industry P/E of 22.4.
Roadmap: The company is growing capacity in steel and power while using captive mines to support its cost base. An integrated model lets it capture margin at several steps of production.
What to watch: Track capacity additions, captive mine output and power plant performance.
Why Oil India Features Among These Steel and Power, Oil Explorer and Pharma Stocks
Among the integrated steel, crude oil and medicine shares on this list, Oil India is a public sector company that explores for and produces crude oil and natural gas, mainly in Assam and other parts of the country, and it also operates a crude pipeline in the North East.
In the June 2026 quarter, revenue grew 47.0% year on year to Rs 13,236 crore, while net profit rose 96.8% to Rs 4,027 crore. Revenue rose from Rs 27,048 crore in FY22 to Rs 35,877 crore in FY26, a compound annual growth rate of 7.3%.
Net profit grew from Rs 7,040 crore in FY25 to Rs 7,551 crore in FY26, a rise of 7.3%. The company has a return on equity of 11.4%, a debt to equity ratio of 0.65 and a market capitalisation of Rs 72,563 crore. The stock trades at a P/E of 7.6, above the industry P/E of 7.2.
Roadmap: The company is stepping up exploration and development spending and building a presence in refining and clean energy through its group companies. Steady production supports earnings and dividends.
What to watch: Track crude oil prices, production volumes and progress on new exploration blocks.
Why Sun Pharma Features Among These Steel and Power, Oil Explorer and Pharma Stocks
Among the three companies on this list, Sun Pharmaceutical Industries is India’s largest pharmaceutical company by market value, with branded generics in India, generics in the United States and a growing specialty medicines business for skin and eye care.
The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2.
Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%. Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%. In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore.
Roadmap: The company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.
What to watch: Track specialty product launches, United States approvals and domestic prescription trends.
Sarda Energy vs Oil India vs Sun Pharma on Key Financials
The table below sets the three steel and power, oil explorer and pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Sarda Energy | 3,964 | 5,928 | 10.6% | 1,063 | 17.9% |
| Oil India | 27,048 | 35,877 | 7.3% | 7,551 | 21.0% |
| Sun Pharma | 39,730 | 61,674 | 11.6% | 11,565 | 18.8% |
Sarda Energy posts the highest return on equity in this group at 15.0%. Sun Pharma combines the largest FY26 revenue at Rs 61,674 crore with the fastest revenue growth, a 11.6% compound annual rate. A useful habit with steel and power, oil explorer and pharma stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several ferro alloy, upstream oil and specialty drug stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Sarda Energy | 1,713 | 1,717 | 0.2% |
| Oil India | 9,006 | 13,236 | 47.0% |
| Sun Pharma | 14,316 | 16,024 | 11.9% |
Key Risks to Check Before Investing in Steel and Power, Oil Explorer and Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these steel and power, oil explorer and pharma stocks, the main points are: Long-term integrated steel, crude oil and medicine shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio. Tracking promoter holding and management commentary adds context when you study integrated steel, crude oil and medicine shares.
- Commodity prices. Selling prices follow global and domestic markets.
- Oil and gas prices. Earnings follow crude oil, gas and refining margins.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter steel and power, oil explorer and pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Steel and Power, Oil Explorer and Pharma Stocks
Steel and power, oil explorer and pharma stocks reward investors who follow demand trends, order books and margins together. Sarda Energy, Oil India and Sun Pharma each have a clear plan to grow. Based on the 10 November 2026 close, Sarda Energy trades at Rs 439.95, Oil India at Rs 439 and Sun Pharma at Rs 1,904.5. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these steel and power, oil explorer and pharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track steel and power, oil explorer and pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are steel and power, oil explorer and pharma stocks?
Ans. Steel and power, oil explorer and pharma stocks are listed companies that make steel, ferro alloys and power, explore for and produce crude oil and natural gas, and develop and sell generic and specialty medicines in India and abroad. Their earnings depend on steel and alloy demand, oil and gas output and prescription demand. This list looks at three of them, Sarda Energy, Oil India and Sun Pharma, using reported FY22 to FY26 financials and the 10 November 2026 closing prices.
Which steel and power, oil explorer and pharma stocks are covered in this list?
Ans. This list covers Sarda Energy, Oil India and Sun Pharma. Based on the 10 November 2026 close, Sarda Energy traded at Rs 439.95, Oil India at Rs 439 and Sun Pharma at Rs 1,904.5. Their return on equity ranges from 11.4% to 15.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.3% to 11.6%.
Why do steel and power, oil explorer and pharma stocks have a strong future roadmap in India?
Ans. Steel and power, oil explorer and pharma stocks have a strong roadmap in India because rising infrastructure spending, steady energy needs and growing global demand for medicines keep widening the market for these companies. The main drivers are as follows. Steel and power. Construction and industry need steady steel. Oil and gas. Homes and factories need reliable fuel. Pharma. Specialty medicines find wider markets. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Sarda Energy performed financially?
Ans. Revenue rose from Rs 3,964 crore in FY22 to Rs 5,928 crore in FY26, a compound annual growth rate of 10.6%. Net profit grew from Rs 808 crore in FY22 to Rs 1,063 crore in FY26, which works out to a compound annual growth rate of 7.1%. In the June 2026 quarter, revenue grew 0.2% year on year to Rs 1,717 crore, while net profit rose 9.4% to Rs 463 crore. The company has a return on equity of 15.0%, a debt to equity ratio of 0.36 and a market capitalisation of Rs 16,079 crore. The stock trades at a P/E of 14.0, below the industry P/E of 22.4. Looking ahead, the company is growing capacity in steel and power while using captive mines to support its cost base. An integrated model lets it capture margin at several steps of production.
How has Oil India performed financially?
Ans. Revenue rose from Rs 27,048 crore in FY22 to Rs 35,877 crore in FY26, a compound annual growth rate of 7.3%. Net profit grew from Rs 7,040 crore in FY25 to Rs 7,551 crore in FY26, a rise of 7.3%. In the June 2026 quarter, revenue grew 47.0% year on year to Rs 13,236 crore, while net profit rose 96.8% to Rs 4,027 crore. The company has a return on equity of 11.4%, a debt to equity ratio of 0.65 and a market capitalisation of Rs 72,563 crore. The stock trades at a P/E of 7.6, above the industry P/E of 7.2. Looking ahead, the company is stepping up exploration and development spending and building a presence in refining and clean energy through its group companies. Steady production supports earnings and dividends.
How has Sun Pharma performed financially?
Ans. Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%. Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%. In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2. Looking ahead, the company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.
What risks should investors check before buying steel and power, oil explorer and pharma stocks?
Ans. Investors should check a few risks before buying steel and power, oil explorer and pharma stocks. Commodity prices. Selling prices follow global and domestic markets. Oil and gas prices. Earnings follow crude oil, gas and refining margins. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of steel and power, oil explorer and pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 10 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.